JD Supra: Mergers

MARCH 31, 2025

Welcome to our ninth annual report on US securities class actions filed against publicly traded life sciences companies, which include pharmaceutical, biotechnology, medical device, and healthcare companies. By: Goodwin

Securities 183

Securities Pharmaceutical Medical Public Trading 183

OfficeHours

JULY 18, 2023

In this industry, owning 50 to 100 or more veterinary centers gives you procurement advantages in that you can buy much higher volumes of suppliers (syringes, medical equipment, etc.) Acquisition Expertise At their core, private equity firms are mergers and acquisitions specialists.

Private Equity 130

Private Equity Equities Investment Mergers and Acquisitions 130

Focus Investment Banking

JUNE 13, 2023

according to a recent report by researchers from the Harvard Medical School and the Harvard Business School that was published in JAMA Internal Medicine. Formerly owned by Tahoe Investment Group, which bought the company in April 2017, Alliance was acquired by Akumin, a publicly traded company, in June 2021 for $820 million.

Hospitality 52

Hospitality Private Equity Mergers and Acquisitions Medical 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

For example, early in 2021, Zimmer Biomet Holdings announced that it would spin off its spine and dental businesses into a new publicly traded company as a way to “optimize resource allocation” among its remaining businesses. Biopharma favoring partnerships over M&A, with biopharma transactions in 2021 being a volume story.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

In the US, the Federal Trade Commission and the Department of Justice under the Biden administration have shifted their priorities and rhetoric in favor of tougher enforcement, with consolidation in the tech sector being one of their top targets. Focus on new potential theories of harm, such as the impact of mergers on labor markets.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 22, 2025

Public company deals: Smaller bites in more focused therapeutic areas The landscape for public company sales in the life sciences sector in 2024 was notably quieter than expected, with anticipated high-profile deals failing to materialize. Similarly, Novo Holdings $16.5

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64